Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: A randomized, placebo-controlled, double-blind study

Oncologist

Volumn 13, Issue 3, 2008, Pages 337-346

  Strasser, Florian ^a   Demmer, Ruth ^a   Böhme, Christel ^a   Schmitz, Shu Fang Hsu ^c   Thuerlimann, Beat ^a,b   Cerny, Thomas ^a   Gillessen, Silke ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

Docetaxel; Glutamine; Neuropathy; Paclitaxel; Prevention; Taste alterations

Indexed keywords

DOCETAXEL; GLUTAMINE; MALTODEXTRIN; PACLITAXEL; PLACEBO; ZINC;

ADULT; AGE DISTRIBUTION; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BITTER TASTE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; GENDER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SENSORY NEUROPATHY; STATISTICAL MODEL; STOMACH CANCER; STOMATITIS; SWEETNESS; TASTE; VISUAL ANALOG SCALE; VOMITING; ZINC DEFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; DYSGEUSIA; FEMALE; GLUTAMINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; RISK FACTORS; TASTE; TAXOIDS; TREATMENT OUTCOME;

EID: 43549104915     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0217     Document Type: Article

References (51)

1. Pellegrini F, Budman DR. Review: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005;23:264-273.
2. Persohn E, Canta A, Schoepfer S et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005;41:1460-1466.
3. Pace A, Nistico C, Cuppone F et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: A schedule or a dose issue? Clin Breast Cancer 2007;7:550-554.
4. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-1642.
5. Argyriou AA, Polychronopoulos P, Koutras A et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 2006;14:223-229.
6. Augusto C, Pietro M, Cinzia M et al. Peripheral neuropathy due to paclitaxel: Study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neurooncol 2008;86:89-99.
7. Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2007 Aug 21; [Epub ahead of print].
8. Heckmann JG, Heckmann SM, Lang CJ et al. Neurological aspects of taste disorders. Arch Neurol 2003;60:667-671.
9. Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: A review of current knowledge. Support Care Cancer 2001;9:575-580.
10. Cella D, Peterman A, Hudgens S et al. Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-taxane (FACT-taxane). Cancer 2003;98:822-831.
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Publish Date: August 9, 2006. Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed September 3, 2007.
12. Wickham RS, Rehwaldt M, Kefer C et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999;26:697-706.
13. Huschka MM, Mandrekar SJ, Schaefer PL et al. A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. Cancer 2007;109:787-795.
14. Morton RF, Sloan JA, Grothey A et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. J Clin Oncol 2005;23 (suppl 16):8087.
15. Sonis ST, Fey EG. Oral complications of cancer therapy. Oncology (Williston Park) 2002;16:680-686; discussion 686, 691-692, 695.
16. Komurcu S, Nelson KA, Walsh D et al. Gastrointestinal symptoms among inpatients with advanced cancer. Am J Hosp Palliat Care 2002;19:351-355.
17. Bernhardson BM, Tishelman C, Rutqvist LE. Chemosensory changes experienced by patients undergoing cancer chemotherapy: A qualitative interview study. J Pain Symptom Manage 2007;34:403-412.
18. Brisbois TD, Hutton JL, Baracos VE et al. Taste and smell abnormalities as an independent cause of failure of food intake in patients with advanced cancer - an argument for the application of sensory science. J Palliat Care 2006;22:111-114.
19. Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 2007;33:156-165.
20. Rubenstein EB, Peterson DE, Schubert M et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(9 suppl):2026-2046.
21. Ripamonti C, Zecca E, Brunelli C et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998;82:1938-1945.
22. Halyard MY, Jatoi A, Sloan JA et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 2007;67:1318-1322.
23. Savarese DM, Savy G, Vahdat L et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29:501-513.
24. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 1996;279:410-415.
25. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 1999;41:107-116.
26. Yoshida S, Kaibara A, Ishibashi N et al. Glutamine supplementation in cancer patients. Nutrition 2001;17:766-768.
27. Lai HS, Lee JC, Lee PH et al. Plasma free amino acid profile in cancer patients. Semin Cancer Biol 2005;15:267-276.
28. Buchman AL. Glutamine: Commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 2001;74:25-32.
29. Garcia-de-Lorenzo A, Zarazaga A, Garcia-Luna PP et al. Clinical evidence for enteral nutritional support with glutamine: A systematic review. Nutrition 2003;19:805-811.
30. Vahdat L, Papadopoulos K, Lange D et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001;7:1192-1197.
31. Stubblefield MD, Vahdat LT, Balmaceda CM et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005;17:271-276.
32. Jacobson SD, Loprinzi CL, Sloan JA et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 2003;1:274-278.
33. Sacks GS. Glutamine supplementation in catabolic patients. Ann Pharmacother 1999;33:348-354.
34. Garlick PJ. Assessment of the safety of glutamine and other amino acids. J Nutr 2001;131(9 suppl):2556S-2561S.
35. Li Y, Yu Z, Liu F et al. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: A prospective randomized trial. Tumori 2006;92:396-401.
36. Steingruber R, Gillessen S, Böhme C et al. Development of an assessment instrument for chemotherapy associated dysgeusia and its implications for patients. Eur J Cancer Suppl 2005;3:446a.
37. Knecht M, Hẗtenbrink KB, Hummel T. [Smell and taste disorders]. Schweiz Med Wochenschr 1999;129:1039-1046. German.
38. Sloan JA, Cella D, Frost M et al.; Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002;77:367-370.
39. Scheid C, Hermann K, Kremer G et al. Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutrition 2004;20:249-254.
40. Cerchietti LC, Navigante AH, Lutteral MA et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-andneck cancer. Int J Radiat Oncol Biol Phys 2006;65:1330-1337.
41. Daniele B, Perrone F, Gallo C et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind, placebo controlled, randomised trial. Gut 2001;48:28-33.
42. Wang WS, Lin JK, Lin TC et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. The Oncologist 2007;12:312-319.
43. Ward E, Smith M, Henderson M et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 2007 Aug 29; [Epub ahead of print].
44. Ward E, Picton S, Reid U et al. Oral glutamine in paediatric oncology patients: A dose finding study. Eur J Clin Nutr 2003;57:31-36.
45. Cavaletti G, Bogliun G, Marzorati L et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004;15:1439-1442.
46. Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109:322-331.
47. Davis ID, Kiers L, MacGregor L et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005;11:1890-1898.
48. Argyriou AA, Chroni E, Koutras A et al. Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of vitamin E supplementation. J Pain Symptom Manage 2006;32:237-244.
49. Maestri A, De Pasquale Ceratti A, Cundari S et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91:135-138.
50. Melli G, Jack C, Lambrinos GL et al. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis 2006;24:525-530.
51. Kirchmair R, Tietz AB, Panagiotou E et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: Taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther 2007;15:69-75.